Macrolide Pharmaceuticals Inks 18,500 SF Relocate to LINX in Watertown via C&WOctober 23, 2017 - By The Real Reporter
BOSTON– Macrolide Pharmaceuticals, a preclinical-stage company developing antibiotic compounds to battle bacterial threats, will expand and relocate to 18,542 square feet of space within the LINX building in Watertown in a lease brokered Cushman & Wakefield for Boylston Properties.
Located at 490 Arsenal Way, LINX is a 185,000-square-foot creative office and lab building in the East End of Watertown, a neighborhood undergoing a tremendous renaissance. The two-story building opened in June 2017 and includes numerous amenities highlighted by an acre of outdoor green and recreation space, a 33’ high lobby area with a café, bike storage for 78 bicycles and a high-end shower and locker facility. LINX also offers abundant free parking and a private shuttle bus to Harvard Square and the MBTA Red Line, a 10-12 minute ride.
It is Cushman & Wakefield’s second laboratory space lease in LINX, following C4 Therapeutics in July. “With its proximity to Boston and Cambridge, LINX continues to attract top-notch life science companies,” said Bill McQuillan, President of Boylston Properties. “Life sciences companies appreciate that this property is in a walkable, urban neighborhood with new housing, restaurants, retail and hotels.”
“LINX is a spectacular building with first-rate laboratory space that allows us to expand in Watertown,” said Dr. Lawrence Miller, CEO of Macrolide. “We’ve grown up in Watertown, appreciate the proximity to other biotech and pharma companies, and we’re committed to being part of the growth and revitalization of the area in and around Arsenal Yards.”
Duncan Gratton, Executive Director, and , represented Boylston Properties, while Macrolide Pharmaceuticals was represented by Don Domoretsky and Bryan Sparkes of JLL.
“We are very pleased to land another life science company at LINX,” said Gratton. “We continue to see strong demand from Cambridge and the surrounding area and we expect additional commitments to be announced very shortly.Duncan Gratton
Cushman & Wakefiled